Arrillaga-Romany, I., Trippa, L., Fell, G., Lee, E. Q., Rahman, R., Touat, M., McCluskey, C., Bruno, J., Gaffey, S., Drappatz, J., Lassman, A., Galanis, E., Ahluwalia, M., Colman, H., Nabors, L. B., Hepel, J., Elinzano, H., Kaley, T., Mellinghoff, I. K., Schiff, D., Chukwueke, U., Beroukhim, R., Nayak, L., McFaline-Figueroa, J. R., Batchelor, T., Lu-Emerson, C., Bi, W. L., Arnaout, O., Peruzzi, P., Haas-Kogan, D., Tanguturi, S., Cagney, D., Aizer, A., Welch, M., Doherty, L., Lavallee, M., Fisher-Longden, B., Dowling, S., Geduldig, J., Watkinson, F., Santagata, S., Meredith, D., Chiocca, E. A., Reardon, D., Ligon, K., Alexander, B., & Wen, P. (2021). cTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-oncology, 23, vi59. http://access.bl.uk/ark:/81055/vdc_100146090606.0x00002e